Aster DM Quality Care Limited share price

Key numbers

Market cap

₹ 66,195 Cr

Current price

₹ 759.40

52-week high / low

₹ 891 / 519

Stock P/E

123.5

Book value

₹ 88.8

Dividend yield

0.53%

ROCE

10.9%

ROE

9.7%

Debt to equity

0.49

Sales growth (3 yrs)

15.7%

Profit growth (3 yrs)

-3.0%

1-year return

20.0%

About Aster DM Quality Care Limited

Aster DM Quality Care Limited operates as an integrated healthcare provider in India. The company operates through four healthcare brands including Aster DM, CARE Hospitals, Evercare, and KIMSHEALTH. It offers comprehensive healthcare services including primary, secondary, tertiary and quaternary care across key areas including oncology, cardiac sciences, neurosciences, gastro sciences, orthopedics, nephrology, organ transplantation, mother and childcare, and critical care. In addition, the company operates retail pharmacies and optical outlets. Aster DM Quality Care Limited was formerly known as Aster DM Healthcare Limited and changed its name to Aster DM Quality Care Limited in July 2026. The company was founded in 1987 and is based in Hyderabad, India.

Quarterly results

Consolidated figures in ₹ crores

Concall summary (2026-08-12)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

• I am delighted to share that Aster DM delivered a strong start to FY27, with revenue increasing 22% year -on-year to Rs.
• Quality Care delivered a standout quarter, with revenue growing 19% YoY to INR 1,287 Cr and Operating EBITDA surging 32% YoY to 299 Cr, and margin expansion of 216 bps reaching 23.2% in Q1FY27.

Growth & demand

• The EBITDA Margin expanded by 170 bps YoY to 22.2%. • Revenue growth was driven by higher patient volumes supported by higher realizations driven by an increasingly complex case mix.
• This was supported by 62% YoY growth in Medical Value Travel (MVT) revenue on account of addition of new geographies. • EBITDA growth outpaced revenue growth, unlocking operating leverage through material cost savings and stronger fixed cost absorption.

Margins & costs

• In our Emerging Units, EBITDA surged by 240% YoY, with margins more than doubling to 12.4% with 640 bps YoY ex pansion.
• 277 Cr, while the operating EBITDA margin expanded by 117 basis points to 21.1%.

Capex & expansion

• Before diving into our Q1 numbers, I want to clearly articulate our framework for value creation and the core strategic priorities that will drive our growth going forward. • Network Expansion • Clinical Excellence • Service Excellence driven through digital enablement, and an effective and empowered team.
• We have a clear roadmap to add over 4,170 beds over the next 3 to 4 years, taking our total capacity over 15,000 beds. • Crucially, 53% of this expansion is brownfield -led, enabling us to leverage existing infrastructure and talent for faster gestation, lower execution risk, and higher ROCE.

Balance sheet & cash

• In closing, the exceptional momentum across both platforms, backed by robust clinical growth, strong operational leverage, and disciplined expansion, gives us immense confidence as we step forward as one integrated enterprise.
• At the combined level there is a net debt of INR 1162 Crore as on 30 June 2026.

Peers in Medical Care Facilities

• Apollo Hospitals Enterprise Limited
• Max Healthcare Institute Limited
• Manipal Health Enterprises Limited
• Fortis Healthcare Limited
• Global Health Limited
• Narayana Hrudayalaya Limited
• Krishna Institute of Medical Sciences Limited
• Rainbow Children's Medicare Limited
• Park Medi World Limited
• Yatharth Hospital & Trauma Care Services Limited